Progress in cancer gene therapy

Acta Oncologica

Volumn 38, Issue 6, 1999, Pages 675-683

  Kouraklis, Gregory ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

CANCER THERAPY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; TUMOR REJECTION;

CLINICAL TRIALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOGENETICS; NEOPLASMS; ONCOGENES;

EID: 0032851758     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699432815     Document Type: Review

References (91)

1. McDonnell TJ, Meyn RE, Robertson LE. Implications of apoptotic cell death regulation in cancer therapy. Sem Cancer Biol 1995; 6: 53-60.
2. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strans M. Adenovirally transferred p16 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997; 3: 316-9.
3. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-2.
4. Friedmann T. Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 1992; 70(S): 1810-7.
5. Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector-mediated transduction of k-ras antisense RNA into human cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993; 4: 451-60.
6. Rosenberg SA. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Hum Gene Ther 1992; 3: 75-90.
7. Huber BE, Austin EA, Good SS, Knick VC, Tobbels S, Richards CA. In vivo antitumor activity of 5-fluorocytisine on human colorectal carcinoma cells genetically modified to express cytocine deaminase. Cancer Res 1993; 53: 4619-26.
8. Ohwada A, Hirschowitz EA, Crystal RG. Regional delivery of an adenovirus containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum Gene Ther 1996; 7: 1567-76.
9. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosin deaminase for tumor specific gene therapy. Hum Gene Ther 1995; 6: 881-93.
10. Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 1997; 57: 461-5.
11. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-tk gene involves an immune component. Cancer Res 1994; 54: 6226-34.
12. Elsami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996; 3: 85-92.
13. Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996; 56: 2697-702.
14. Mesnil M, Piccoli C, Tirabi G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-5.
15. Barba D, Hardin J, Sadelin M, Gage FH. Development of antitumor immunity following thymidine kinase-based killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-52.
16. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 co-stimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523-32.
17. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Nutl Acad Sci USA 1993; 90: 7024-8.
18. Tong XW, Block A, Chen SH, et al. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol 1996; 61: 175-9.
19. Yee D, McGuire SE, Brunner N, et al. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther 1996; 7: 1251-7.
20. Kim JH, Kim SH, Kolozsvary A, Brown SL, Lim OB, Freytag SO. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 1995; 33: 861-8.
21. Khil MS, Kim JH, Mullen CA, Lim SH, Freytag SO. Radiosensitization by 5-fluocytocine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res 1996; 2: 53-7.
22. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-55.
23. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994; 86: 1458-62.
24. Lesson-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995; 6: 395-405.
25. Xu M. Kumar D, Srinivas S, et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a by stander mechanism without evidence of toxicity. Hum Gene Ther 1997; 8: 177-85.
26. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2: 985-91.
27. Roth JA. Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wild-type (normal) p53. Hum Gene Ther 1996; 7: 861-74.
28. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
29. Gjerset RA, Turla ST, Sobol RE. Scalise JJ, Mercola D, Collins H, Hopkins PJ. Use of wild-type p53 to achieve complete treatment sensitizalion of tumor cells expressing endogenous mutant p53. Mol Carcinog 1995; 14: 275-85.
30. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorae Cardiovasc Surg 1996; 112: 1372-7.
31. Skorki T, Skorska-Nicborowska M, Barletta C, et al. Highly efficient elimination of Philadelphia leukemic cells by exposure to berabl antisense oligonucleotides combined with mafosfamide. J Clin Invest 1993; 92: 194-202.
32. Izquierdo M, Leevers SJ, Marshall CJ, Cantrell D. p21ras couples the T cell antigen receptor to extracellular signal-related kinase 2 in T lymphocytes. J Exp Med 1993; 178: 1199-208.
33. Raftopoulos J, Kouraklis G, Dysfunction of the E-cadherin catenin cell adhesion cascade in epithelial cancers. Oncol Rep 1996; 3: 793-803.
34. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of the human NDR1. Science 1992; 257: 99-103.
35. Fearon F.R. Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
36. Gansbacher B, Bannerji R, Daneils B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated g-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990; 50: 7820-5.
37. Dranoff G, Jaffee E. Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43.
38. Porgador A, Banneji R. Waanabe Y, Feldman. M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-g gene-inserted tumor cells. J Immunol 1993; 150: 1458-70.
39. Vieweg J, Rosenthal FM, Bannerji R, et al. Immunotherapy of prostate cancer in the dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994; 54: 1760-5.
40. Arthur JF, Butterfield LH, Roth MD, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4: 17-25.
41. Paillard F. Cancer gene therapy annual conference 1997: trends and news. Hum Gene Ther 1998; 9: 283-6.
42. Morel A, Delacoste A, Fernander N, et al. Does preventing vaccination with engineered tumor cells work in cancer-prone transgenic mice? Cancer Gene Ther 1998; 5: 92-100.
43. Salvadori S, Gansbacher B. Wernick I, Tirelli S, Zier K. B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum Gene Ther 1995; 6: 1299-306.
44. +-mediated rejection of established tumors. Hum Gene Ther 1997; 8: 477-88.
45. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol 1993; 11: 199-212.
46. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by B7 countereceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-102.
47. + T cells by B-7 transfected melanoma cells. Science 1993; 259: 368-70.
48. Wu TC, Huang AYC, Jaffec EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-I expression in tumor rejection. J Exp Med 1995; 182: 1415-21.
49. Chong H, Hutchinson G, Hart IR, Vile RG. Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum Gene Ther 1996; 7: 1771-9.
50. Crystal RG. Transfer of gene to humans: early lessons and obstacles to success. Science 1995; 270: 404-10.
51. Miller AD. Retrovirus packaging cells. Hum Gene Ther 1990; 1: 5-14.
52. Roe TY, Reynolds TC, Yu G, Brown PO. Integration of marine leukemia virus DNA depends on mitosis. EMBO J 1993; 12: 2099-108.
53. Herrmann F. Cancer gene therapy: principles, problems, and perspectives. J Mol Med 1995; 73: 157-63.
54. Letvin NL. Progress in the development of an HIV-1 vaccine. Science 280: 1875-9
55. Dull T, Zufferey R, Kelly M, et al. A third generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-71.
56. Horwitz, MS. Adenoviridae and their replication. In: Fields BN, Knipe DM, eds. Virology, 2nd edn. New York: Raven Press, 1990: 1679-721.
57. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 1993; 3: 219-23.
58. Li Q, Kay MA, Finegold M, Stratford-Perricaudet I.D, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993; 4: 403-9.
59. Clarke MF, Apel IJ, Benedict MA, Eipers PG, Sumantran V, Gonzalezgarcia M. A recombinant bel-x(s) adenovirus selectively induces apoplosis in cancer cells but not in normal bone marrow cells. Proc Natl Acad Sci USA 1995; 92: 11024-8.
60. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits El- deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-11.
61. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-200.
62. Engelhardt JF, Litzky L, Wilson JM, Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2A. Hum Gene Ther 1994; 5: 1217-29.
63. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996; 217: 11-22.
64. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and b-galactosidase. Proc Natl Acad Sci USA 1996; 93: 5731-6.
65. Dai Y, Schwarz EM, Gu D, Zhang W, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of both factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-5.
66. Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN. Gene therapy for hemophilia B: host immuno- suppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995; 6: 1039-44.
67. Bridge E, Medghalchi S, Ubol S, Leesong M, Ketner G. Adenovirus early region 4 and viral DNA synthesis. Virology 1993; 193: 794-801.
68. Wang Q, Jia XC, Finer MH. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther 1995; 2: 775-83.
69. Wang Q, Finer MH. Second generation adenovirus vectors. Nat Med 1996; 2: 714-6.
70. Gao GP, Yang Y, Wilson JM. Biology of adenoviral vectors deleted of E1 and E4 for liver-directed gene therapy. J Virol 1996; 70: 8934-43.
71. Halbert CL, Alexander IE, Wolgamot GM, Miller AD. Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells. J Virol 1995; 69: 1473-9.
72. Latchman DS. Herpes simplex virus vectors for gene therapy. Mol Biotechnol 1994; 2: 179-95.
73. Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta. Ann Surg Oncol 1995; 2: 151-9.
74. Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994; 54: 5552-5.
75. Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 1993; 261: 209-11.
76. Cristiano RJ, Smith LC, Kay MA, Brinkley BR, Woo SL. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA 1993; 90: 11548-52.
77. Bunnell BA, Askari FK, Wilson JM. Targeted delivery of antisense oligonucleotides by molecular conjugates. Somat Cell Mol Genet 1992; 18: 559-69.
78. Cotten M, Wagner E, Zatloukal K, Philips S, Curiel DT, Birnstiel ML. High-efficiency receptor-mediated delivery of small and large (48 kb) gene constructs using the endosome- disruption activity of defective or chemically inactivated adenovirus pertieles. Proc Natl Acad Sci USA 1992; 89: 6094-8.
79. Trial: Immunotherapy of malignancy by in vivo gene transfer into tumors. Hum Gene Ther 1992; 3: 339-410.
80. Wagner E, Zenke M, Cotten M, Beug H, Birnstiel ML. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci USA 1990; 87: 3410-4.
81. Ascadi G, Jiao SS, Jani A, Duke D, Williams P, Chong W. Direct gene transfer and expression into rat heart in vivo. New Biol 1991; 3: 71-81.
82. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860-4.
83. Cheng L, Ziegelhoffer PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993; 90: 4455-9.
84. Nicolet CM, Burkholder JK, Gan J, Culp J, Kashmiri SV, Schlom J. Expression of a tumor-reactive antibody-interleukin-2 fusion protein alter in vivo particle-mediated gene delivery. Cancer Ther 1995; 2: 161-70.
85. Sobol R, Scanlon KJ. Clinical protocols list. Cancer Gene Ther 1995; 2: 225-34.
86. Jin X, Nguyen D, Zhang WW, Kyritsis AP, Roth JA. Cell cycle arrest and inhibition of tumor cell proliferation by the p16, INK4 gene mediated by an adenovirus vector. Cancer Res 1995; 55: 3250-3.
87. Xu HJ, Zhou Y, Seigne J, Perng GS, Mixon M, Zhang C. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 1996; 56: 2245-9.
88. Cristiano RJ, Smith LC, Woo SL. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA 1993; 90: 11548-52.
89. Curiel DT, Wagner E, Cotten M, Birnstiel ML, Agarwal S, Li C. High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum Gene Ther 1992; 3: 147-54.
90. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994; 266: 1373-6.
91. Ghazal P, Lubon H, Fleckenstein B, Hennighausen L. Binding of transcription factors and creation of a large nucleoprotein complex on the human cytomegatovirus enhancer. Proc Natl Acad Sci USA 1987; 84: 3658-62.